Literature DB >> 24634163

Dose-specific adverse drug reaction identification in electronic patient records: temporal data mining in an inpatient psychiatric population.

Robert Eriksson1, Thomas Werge, Lars Juhl Jensen, Søren Brunak.   

Abstract

BACKGROUND: Data collected for medical, filing and administrative purposes in electronic patient records (EPRs) represent a rich source of individualised clinical data, which has great potential for improved detection of patients experiencing adverse drug reactions (ADRs), across all approved drugs and across all indication areas.
OBJECTIVES: The aim of this study was to take advantage of techniques for temporal data mining of EPRs in order to detect ADRs in a patient- and dose-specific manner.
METHODS: We used a psychiatric hospital's EPR system to investigate undesired drug effects. Within one workflow the method identified patient-specific adverse events (AEs) and links these to specific drugs and dosages in a temporal manner, based on integration of text mining results and structured data. The structured data contained precise information on drug identity, dosage and strength.
RESULTS: When applying the method to the 3,394 patients in the cohort, we identified AEs linked with a drug in 2,402 patients (70.8 %). Of the 43,528 patient-specific drug substances prescribed, 14,736 (33.9 %) were linked with AEs. From these links we identified multiple ADRs (p < 0.05) and found them to occur at similar frequencies, as stated by the manufacturer and in the literature. We showed that drugs displaying similar ADR profiles share targets, and we compared submitted spontaneous AE reports with our findings. For nine of the ten most prescribed antipsychotics in the patient population, larger doses were prescribed to sedated patients than non-sedated patients; five antipsychotics [corrected] exhibited a significant difference (p<0.05). Finally, we present two cases (p < 0.05) identified by the workflow. The method identified the potentially fatal AE QT prolongation caused by methadone, and a non-described likely ADR between levomepromazine and nightmares found among the hundreds of identified novel links between drugs and AEs (p < 0.05).
CONCLUSIONS: The developed method can be used to extract dose-dependent ADR information from already collected EPR data. Large-scale AE extraction from EPRs may complement or even replace current drug safety monitoring methods in the future, reducing or eliminating manual reporting and enabling much faster ADR detection.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24634163      PMCID: PMC3975083          DOI: 10.1007/s40264-014-0145-z

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  29 in total

Review 1.  The cost of adverse drug reactions.

Authors:  Sophie Gautier; Hélène Bachelet; Régis Bordet; Jacques Caron
Journal:  Expert Opin Pharmacother       Date:  2003-03       Impact factor: 3.889

2.  Data-driven prediction of drug effects and interactions.

Authors:  Nicholas P Tatonetti; Patrick P Ye; Roxana Daneshjou; Russ B Altman
Journal:  Sci Transl Med       Date:  2012-03-14       Impact factor: 17.956

Review 3.  Tolerability of atypical antipsychotics.

Authors:  C Stanniland; D Taylor
Journal:  Drug Saf       Date:  2000-03       Impact factor: 5.606

Review 4.  Mining electronic health records: towards better research applications and clinical care.

Authors:  Peter B Jensen; Lars J Jensen; Søren Brunak
Journal:  Nat Rev Genet       Date:  2012-05-02       Impact factor: 53.242

Review 5.  Drug induced nightmares--an etiology based review.

Authors:  J F Pagel; P Helfter
Journal:  Hum Psychopharmacol       Date:  2003-01       Impact factor: 1.672

Review 6.  Adverse effects of antiepileptic drugs.

Authors:  Piero Perucca; Frank G Gilliam
Journal:  Lancet Neurol       Date:  2012-07-24       Impact factor: 44.182

Review 7.  Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.

Authors:  Stefan Leucht; Andrea Cipriani; Loukia Spineli; Dimitris Mavridis; Deniz Orey; Franziska Richter; Myrto Samara; Corrado Barbui; Rolf R Engel; John R Geddes; Werner Kissling; Marko Paul Stapf; Bettina Lässig; Georgia Salanti; John M Davis
Journal:  Lancet       Date:  2013-06-27       Impact factor: 79.321

8.  Pharmacovigilance using clinical notes.

Authors:  P LePendu; S V Iyer; A Bauer-Mehren; R Harpaz; J M Mortensen; T Podchiyska; T A Ferris; N H Shah
Journal:  Clin Pharmacol Ther       Date:  2013-03-04       Impact factor: 6.875

9.  A reference standard for evaluation of methods for drug safety signal detection using electronic healthcare record databases.

Authors:  Preciosa M Coloma; Paul Avillach; Francesco Salvo; Martijn J Schuemie; Carmen Ferrajolo; Antoine Pariente; Annie Fourrier-Réglat; Mariam Molokhia; Vaishali Patadia; Johan van der Lei; Miriam Sturkenboom; Gianluca Trifirò
Journal:  Drug Saf       Date:  2013-01       Impact factor: 5.606

10.  Dictionary construction and identification of possible adverse drug events in Danish clinical narrative text.

Authors:  Robert Eriksson; Peter Bjødstrup Jensen; Sune Frankild; Lars Juhl Jensen; Søren Brunak
Journal:  J Am Med Inform Assoc       Date:  2013-05-23       Impact factor: 4.497

View more
  17 in total

Review 1.  Natural Language Processing for EHR-Based Pharmacovigilance: A Structured Review.

Authors:  Yuan Luo; William K Thompson; Timothy M Herr; Zexian Zeng; Mark A Berendsen; Siddhartha R Jonnalagadda; Matthew B Carson; Justin Starren
Journal:  Drug Saf       Date:  2017-11       Impact factor: 5.606

2.  Finding Cervical Cancer Symptoms in Swedish Clinical Text using a Machine Learning Approach and NegEx.

Authors:  Rebecka Weegar; Maria Kvist; Karin Sundström; Søren Brunak; Hercules Dalianis
Journal:  AMIA Annu Symp Proc       Date:  2015-11-05

3.  Handling Temporality of Clinical Events for Drug Safety Surveillance.

Authors:  Jing Zhao; Aron Henriksson; Maria Kvist; Lars Asker; Henrik Boström
Journal:  AMIA Annu Symp Proc       Date:  2015-11-05

4.  An investigation of single-domain and multidomain medication and adverse drug event relation extraction from electronic health record notes using advanced deep learning models.

Authors:  Fei Li; Hong Yu
Journal:  J Am Med Inform Assoc       Date:  2019-07-01       Impact factor: 4.497

5.  Identification of possible adverse drug reactions in clinical notes: The case of glucose-lowering medicines.

Authors:  Pernille Warrer; Peter Bjødstrup Jensen; Lise Aagaard; Lars Juhl Jensen; Søren Brunak; Malene Hammer Krag; Peter Rossing; Thomas Almdal; Henrik Ullits Andersen; Ebba Holme Hansen
Journal:  J Res Pharm Pract       Date:  2015 Apr-Jun

6.  Patient stratification and identification of adverse event correlations in the space of 1190 drug related adverse events.

Authors:  Eva Roitmann; Robert Eriksson; Søren Brunak
Journal:  Front Physiol       Date:  2014-09-09       Impact factor: 4.566

7.  The SIDER database of drugs and side effects.

Authors:  Michael Kuhn; Ivica Letunic; Lars Juhl Jensen; Peer Bork
Journal:  Nucleic Acids Res       Date:  2015-10-19       Impact factor: 16.971

8.  The digital revolution in phenotyping.

Authors:  Anika Oellrich; Nigel Collier; Tudor Groza; Dietrich Rebholz-Schuhmann; Nigam Shah; Olivier Bodenreider; Mary Regina Boland; Ivo Georgiev; Hongfang Liu; Kevin Livingston; Augustin Luna; Ann-Marie Mallon; Prashanti Manda; Peter N Robinson; Gabriella Rustici; Michelle Simon; Liqin Wang; Rainer Winnenburg; Michel Dumontier
Journal:  Brief Bioinform       Date:  2015-09-29       Impact factor: 11.622

9.  Ensembles of randomized trees using diverse distributed representations of clinical events.

Authors:  Aron Henriksson; Jing Zhao; Hercules Dalianis; Henrik Boström
Journal:  BMC Med Inform Decis Mak       Date:  2016-07-21       Impact factor: 2.796

Review 10.  'Big data' in mental health research: current status and emerging possibilities.

Authors:  Robert Stewart; Katrina Davis
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2016-07-27       Impact factor: 4.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.